{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:20:33Z","timestamp":1774923633987,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":168,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Currently, there are two prognosis staging systems validated for transthyretin amyloidosis (ATTR). We sought to develop a new staging system dedicated to hereditary transthyretin amyloidosis (ATTRv) patients on specific treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>A total of 258 patients diagnosed with ATTRv from two cardiac amyloidosis reference centres in France and Romania were stratified into three disease stages based on NT-proBNP, estimated glomerular filtration rate (eGFR) and global longitudinal strain (GLS). A staging system was created using the following criteria: GLS \u2265 \u221211%, NT-proBNP \u2265 2000 ng\/L and eGFR \u2264 65 mL\/min. Stage I was defined as the presence of none of the criteria. Stage III was defined as GLS \u2265 \u221211% and either one or both NT-proBNP and eGFR criteria, while the remaining patients were defined as Stage II. Stage I patients had a 98.5% (95% CI 94.8\u2013100) 5-year survival rate, Stage II patients 75.1% (95% CI 64.8\u201387.1) and Stage III patients a 29.4% (95% CI 18.6\u201346.5) 5-year survival rate (Stage I vs. Stage II, P = 0.001; Stage II vs. Stage III, P &amp;lt; 0.001). After age is adjusted for, compared to Stage I, the hazard ratio (HR) for death was 9.9 (95% CI 1.28\u201376.27, P = 0.02) for Stage II and 39.75 (95% CI 5.28\u2013299.54, P &amp;lt; 0.001) for Stage III patients. HRs and statistical significance were maintained across different ATTR genotypes. The staging system was validated in a cohort of 138 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We propose a novel staging system for ATTRv patients on specific treatment, based on two biological markers and one echocardiographic parameter, common in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15414","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T02:44:22Z","timestamp":1756953862000},"page":"4125-4139","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A New Staging System for Hereditary Transthyretin Amyloidosis in the Era of Specific Amyloidosis Therapies"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-3291","authenticated-orcid":false,"given":"Gabriela","family":"Neculae","sequence":"first","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy , Bucharest ,","place":["Romania"]},{"name":"Expert Center for Rare Genetic Cardiovascular Diseases, Cardiology Department, \u2018C.C. Iliescu\u2019 Emergency Institute for Cardiovascular Disease , Bucharest ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira","family":"Zaroui","sequence":"additional","affiliation":[{"name":"French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, Henri-Mondor Teaching Hospital , AP\u2013HP, Creteil ,","place":["France"]},{"name":"Cardiology Department, Henri-Mondor Teaching Hospital , Creteil ,","place":["France"]},{"name":"Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Adam","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy , Bucharest ,","place":["Romania"]},{"name":"Expert Center for Rare Genetic Cardiovascular Diseases, Cardiology Department, \u2018C.C. Iliescu\u2019 Emergency Institute for Cardiovascular Disease , Bucharest ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounira","family":"Kharoubi","sequence":"additional","affiliation":[{"name":"French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, Henri-Mondor Teaching Hospital , AP\u2013HP, Creteil ,","place":["France"]},{"name":"Cardiology Department, Henri-Mondor Teaching Hospital , Creteil ,","place":["France"]},{"name":"Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health , Cr\u00e9teil ,","place":["France"]},{"name":"Universit\u00e9 Paris Est Creteil , INSERM, IMRB, Creteil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Funalot","sequence":"additional","affiliation":[{"name":"Cardiology Department, Henri-Mondor Teaching Hospital , Creteil ,","place":["France"]},{"name":"Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health , Cr\u00e9teil ,","place":["France"]},{"name":"Universit\u00e9 Paris Est Creteil , INSERM, IMRB, Creteil ,","place":["France"]},{"name":"Genetics Department, Henri-Mondor Teaching Hospital , Creteil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy , Bucharest ,","place":["Romania"]},{"name":"Department of Hematology, Fundeni Clinical Institute , Bucharest ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxandra","family":"Jurcut","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy , Bucharest ,","place":["Romania"]},{"name":"Expert Center for Rare Genetic Cardiovascular Diseases, Cardiology Department, \u2018C.C. Iliescu\u2019 Emergency Institute for Cardiovascular Disease , Bucharest ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, Henri-Mondor Teaching Hospital , AP\u2013HP, Creteil ,","place":["France"]},{"name":"Cardiology Department, Henri-Mondor Teaching Hospital , Creteil ,","place":["France"]},{"name":"Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health , Cr\u00e9teil ,","place":["France"]},{"name":"Universit\u00e9 Paris Est Creteil , INSERM, IMRB, Creteil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2026021804153676400_ehf215414-bib-0001","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Contemporary reviews in cardiovascular medicine transthyretin (TTR) cardiac amyloidosis","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2026021804153676400_ehf215414-bib-0002","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"Nativi-Nicolau","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026021804153676400_ehf215414-bib-0003","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"2026021804153676400_ehf215414-bib-0004","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/13506129.2021.1950681","article-title":"Association between spinal stenosis and wild-type ATTR amyloidosis","volume":"28","author":"Godara","year":"2021","journal-title":"Amyloid"},{"key":"2026021804153676400_ehf215414-bib-0005","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/J.JACC.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021804153676400_ehf215414-bib-0006","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2018.1531842","article-title":"Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan","volume":"25","author":"Ueda","year":"2018","journal-title":"Amyloid"},{"key":"2026021804153676400_ehf215414-bib-0007","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","article-title":"Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy","volume":"287","author":"Koike","year":"2009","journal-title":"J Neurol Sci"},{"key":"2026021804153676400_ehf215414-bib-0008","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00258-z","article-title":"Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","author":"Waddington-Cruz","year":"2021","journal-title":"Neurol Ther"},{"key":"2026021804153676400_ehf215414-bib-0009","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","journal-title":"Eur Heart J"},{"key":"2026021804153676400_ehf215414-bib-0010","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/J.ACVD.2023.07.003","article-title":"Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France","volume":"116","author":"Damy","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"2026021804153676400_ehf215414-bib-0011","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-020-1309-9","article-title":"Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population","volume":"15","author":"Jercan","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026021804153676400_ehf215414-bib-0012","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/J.JACC.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021804153676400_ehf215414-bib-0013","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/EURHEARTJ\/EHX589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021804153676400_ehf215414-bib-0014","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/EURHEARTJ\/EHAB072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804153676400_ehf215414-bib-0015","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/S13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026021804153676400_ehf215414-bib-0016","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/HUMU.22619","article-title":"Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat"},{"key":"2026021804153676400_ehf215414-bib-0017","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/EHJCI\/JEX244","article-title":"Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021804153676400_ehf215414-bib-0018","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Statist Data Anal"},{"key":"2026021804153676400_ehf215414-bib-0019","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0B013E3182661EB1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"2026021804153676400_ehf215414-bib-0020","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026021804153676400_ehf215414-bib-0021","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ENE.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol"},{"key":"2026021804153676400_ehf215414-bib-0022","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/J.CARDFAIL.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"31","author":"Garcia-Pavia","journal-title":"J Card Fail"},{"key":"2026021804153676400_ehf215414-bib-0023","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/EJHF.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804153676400_ehf215414-bib-0024","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMOA1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021804153676400_ehf215414-bib-0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804153676400_ehf215414-bib-0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.10.013","article-title":"Primary results from APOLLO-B, a phase 3 study of patisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy","author":"Maurer","journal-title":"J Card Fail"},{"key":"2026021804153676400_ehf215414-bib-0027","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/EHJCI\/JEAC049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021804153676400_ehf215414-bib-0028","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/J.JACCAO.2020.05.012","article-title":"Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis","volume":"2","author":"Lee Chuy","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026021804153676400_ehf215414-bib-0029","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/J.JACCAO.2024.03.007","article-title":"Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy","volume":"6","author":"Witteles","year":"2024","journal-title":"Cardio Oncol"},{"key":"2026021804153676400_ehf215414-bib-0030","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1161\/CIRCULATIONAHA.107.724187","article-title":"N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: The African American Study of Kidney Disease and Hypertension (AASK)","volume":"117","author":"Astor","year":"2008","journal-title":"Circulation"},{"key":"2026021804153676400_ehf215414-bib-0031","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1309\/AJCP60HTPGIGFCNK","article-title":"The Effect of Renal Dysfunction on BNP, NT-proBNP, and Their Ratio","volume":"133","author":"Srisawasdi","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2026021804153676400_ehf215414-bib-0032","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.900313","article-title":"Clinical profile and prognosis of hereditary transthyretin amyloid cardiomyopathy: a single-center study in South China","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026021804153676400_ehf215414-bib-0033","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/13506129.2022.2043270","article-title":"Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"29","author":"Barroso","year":"2022","journal-title":"Amyloid"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4125\/66968263\/eschf_12_6_4125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4125\/66968263\/eschf_12_6_4125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:15:45Z","timestamp":1771406145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/4125\/8488162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,3]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15414","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}